Company

CanSino Biologics

康希诺生物

CanSino Biologics (688185.SH, 06185.HK) is a vaccine developer and a Qiming Venture Partners portfolio company, which Qiming's weekly roundups cite as one of its investments that have become leaders in their fields . Its 2025 activity shows a company working both its platform technology and its commercial reach: it built an in-house mRNA platform with proprietary sequence-optimization software and a streamlined CMC process, and its Shanghai subsidiary signed a co-development deal with KeyTech (键凯科技) to push an mRNA vaccine for glioblastoma into clinical study — later co-developing a three-component lipid nanoparticle delivery system (ISL-3C-LNP) with the same partner . On the pipeline side, its inhaled tuberculosis vaccine (adenovirus type-5 vector) won clinical trial approval in Indonesia in 2025, after Phase 1a/1b trials in Canada showed safety and superiority in mucosal immunity as a BCG booster . Commercially, it licensed exclusive Greater China promotion rights for its adsorbed tetanus vaccine to Grand Life Sciences — a deal worth up to RMB 100 million in upfront and milestone payments over ten years — and struck a partnership with SPIMACO that chairman and CEO Yu Xuefeng called a milestone for entering the Middle East and North Africa markets .

AI-generated — may contain errors, please verify.

CanSino BiologicsCompany
康希诺生物
渲染中…
Mentioned in 134 articles

Coverage